Skip to main content

Table 2 Base-case cumulative virological response and HBV resistance probabilities for each rescue therapy

From: Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China

Rescue therapy HBeAg (+)   BeAg (−)   Source
  Cumulative virological response (%) Cumulative resistance (%) Cumulative virological response (%) Cumulative resistance (%)  
ADV monotherapy 1st year: 20.4 1st year: 1.6 1st year: 33.3 1st year: 0 [9]
  2nd year: 33.2 2nd year: 20.7 2nd year: 44.0 2nd year: 16.9 [9]
  3rd year: 38.8 3rd year: 39.5 3rd year: 47.5 3rd year: 31.4 [9]
  4th year: 41.2 4th year: 51.6 4th year: 51.0 4th year: 42.4 [9]
ADV and LAM combination therapy 1st year: 47.0 1st year: 1.0 1st year: 60.0 1st year: 1.0 [29, 30]
  2nd year: 68.0 2nd year: 1.0 2nd year: 76.0 2nd year: 1.0 [29, 30]
   3rd year: 1.0 3rd year: 97.0 3rd year: 1.0 [29, 30]
   4th year: 8.0   4th year: 8.0 [29]
ETV monotherapy§ 1st year: 21.0 1st year: 1.0 1st year: 21.0 1st year: 1.0 [18, 20, 23]
  2nd year: 39.5 2nd year: 10.9 2nd year: 39.5 2nd year: 10.9 [18, 20, 23]
   3rd year: 25.2   3rd year: 25.2 [18, 20, 23]
   4th year: 36.4   4th year: 36.4 [18, 20, 23]
TDF monotherapy§ 1st year: 45.8 1st year: 1.0 1st year: 45.8 1st year: 1.0 [22]
  2nd year: 64.4 2nd year: 2.0 2nd year: 64.4 2nd year: 2.0 [22]
  1. §No separate data for HBeAg(+) and HBeAg(−) cohorts were reported; we assumed that the response and resistant data were similar for both cohorts.